丙肝相关肝硬化患者DAA治疗后临床结局取决于疾病严重程度
该多中心队列纳入868例DAA治疗的HCV肝硬化患者,Child-Pugh A者SVR与无事件生存改善独立相关(aHR 0.47),而Child-Pugh B/C者无此关联;B/C级中MELD下降≥2分未带来临床结局改善。
要点
- Child-Pugh A肝硬化患者获得SVR与临床疾病进展风险降低独立相关。
- Child-Pugh B/C肝硬化患者中SVR与临床疾病进展风险无关。
- Child-Pugh B/C患者MELD下降≥2分未改善2年无事件生存。
核心结论
- DAA诱导的SVR与Child-Pugh A肝硬化患者临床疾病进展风险降低相关,但与Child-Pugh B/C患者无关。
- Child-Pugh B/C肝硬化患者MELD下降≥2分未转化为临床结局改善。
研究设计与样本
- 来自4个肝病门诊的连续DAA治疗的慢性HCV感染肝硬化患者队列研究。
- 共纳入868例患者,中位年龄59岁(IQR 54-65),Child-Pugh A 719例(83%),Child-Pugh B/C 149例(17%)。
主要发现
- Child-Pugh A患者SVR率90%(647例),Child-Pugh B/C患者SVR率81%(120例)。
- 中位随访28个月(IQR 20-36),Child-Pugh A患者102例(14%)发生临床疾病进展,Child-Pugh B/C患者96例(64%)发生。
- Child-Pugh A患者SVR与无事件生存改善独立相关(aHR 0.47;95%CI 0.27-0.82,p=0.007)。
- Child-Pugh B/C患者SVR与无事件生存无独立关联(aHR 1.23;95%CI 0.67-2.26,p=0.51)。
- DAA后12周,Child-Pugh B/C患者28例(19%)MELD下降≥2分,其2年无事件生存与MELD稳定者无差异(47.9%;95%CI 28.7-67.1 vs. 48.9%;95%CI 38.1-59.7,p=0.99)。
临床怎么用
- Child-Pugh A肝硬化患者应积极DAA治疗以降低临床疾病进展风险。
- Child-Pugh B/C肝硬化患者DAA治疗后仍需评估肝移植需求,MELD下降≥2分不预示结局改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: HCV-infected patients with cirrhosis achieve high sustained virological response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic decompensation. We aimed to assess the clinical outcome following DAAs among patients with compensated and decompensated cirrhosis in relation to SVR and changes in model for end-stage liver disease (MELD) score. METHODS: Consecutive DAA-treated chronic HCV-infected patients with cirrhosis from 4 hepatology clinics were included. The primary endpoint in survival analyses was clinical disease progression, defined as liver failure, hepatocellular carcinoma, liver transplantation or death. RESULTS: In total, 868 patients were included with a median age of 59 (IQR 54-65) years; 719 (83%) with Child-Pugh A cirrhosis and 149 (17%) with Child-Pugh B/C cirrhosis. SVR was attained by 647 (90%) Child-Pugh A patients and 120 (81%) Child-Pugh B/C patients. During a median follow-up of 28 (IQR 20-36) months, 102 (14%) Child-Pugh A patients and 96 (64%) Child-Pugh B/C patients experienced clinical disease progression. SVR was independently associated with an improved event-free survival in patients with Child-Pugh A cirrhosis (adjusted hazard ratio [HR] 0.47; 95% CI 0.27-0.82, p = 0.007), but not in patients with Child-Pugh B/C cirrhosis (adjusted HR 1.23; 95% CI 0.67-2.26; p = 0.51). Twelve weeks post-DAAs, 28 (19%) patients with Child-Pugh B/C cirrhosis had ≥2-point MELD decline, but their 2-year event-free survival did not differ from those with a stable MELD (47.9%; 95% CI 28.7-67.1 vs. 48.9%; 95% CI 38.1-59.7, respectively, p = 0.99). CONCLUSIONS: Among patients with chronic HCV infection, DAA-induced SVR was associated with a reduced risk of clinical disease progression in patients with Child-Pugh A cirrhosis but not in patients with Child-Pugh B/C cirrhosis. In Child-Pugh B/C cirrhosis, a ≥2-point MELD decline did not translate into improved clinical outcome. LAY SUMMARY: Chronic HCV infection can be cured with antiviral therapy. In this study, we evaluated the long-term effects of antiviral therapy on liver-related complications in patients with cirrhosis. Our results suggest that patients with compensated cirrhosis who were cured of their HCV infection have a lower rate of complications. In contrast, the rate of complications was not related to virological cure among those with decompensated cirrhosis. While these patients seem to remain in need of liver transplantation, antiviral therapy may lower their priority on the liver transplantation waiting list.
引用
- Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2020. PMID: 33242501. doi:10.1016/j.jhep.2020.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。